ACOG
Alpha Cognition IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$134.80M
P/E Ratio
—
EPS
$-1.18
Beta
2.52
52W High
$11.54
52W Low
$3.75
50-Day MA
$5.59
200-Day MA
$7.13
Dividend Yield
—
Profit Margin
-202.20%
Forward P/E
16.05
PEG Ratio
—
About Alpha Cognition Inc
Alpha Cognition Inc. is a pioneering biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, with a strong emphasis on Alzheimer's disease. Its lead candidate, ACOG-100, is designed to enhance cognitive function in patients and address significant unmet medical needs within the aging population. Driven by a robust R&D strategy and a proprietary neuroscience platform, Alpha Cognition is strategically positioned to revolutionize patient care in this critical area. As the company continues to advance its clinical pipeline and explore new therapeutic avenues, it represents a compelling opportunity for institutional investors navigating the evolving healthcare landscape.
Fundamentals
| Revenue (TTM) | $10.22M |
| Gross Profit (TTM) | $8.30M |
| EBITDA | $-22.62M |
| Operating Margin | -283.70% |
| Return on Equity | -39.80% |
| Return on Assets | -21.70% |
| Revenue/Share (TTM) | $0.58 |
| Book Value | $2.88 |
| Price-to-Book | 2.08 |
| Price-to-Sales (TTM) | 13.19 |
| EV/Revenue | 8.06 |
| EV/EBITDA | -1.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $21.74M |
| Float | $11.04M |
| % Insiders | 9.79% |
| % Institutions | 52.70% |
Analyst Ratings
Consensus ($18.00 target)
1
BuyData last updated: 4/7/2026